focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.35
Bid: 3.30
Ask: 3.40
Change: 0.15 (4.69%)
Spread: 0.10 (3.03%)
Open: 3.20
High: 3.35
Low: 3.20
Prev. Close: 3.20
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Impellam climbs on GBP483 million takeover offer

Wed, 13th Dec 2023 09:55

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

Impellam Group PLC, up 26% at 819.12 pence, 12-month range 580.00p-950.00p. Shares in the staffing firm rise, though back off from new 52-week high, after it says it has agreed to a GBP483.2 million takeover offer from Heather Global PLC, a bidding vehicle for HeadFirst Global BV. The HeadFirst offer values each Impellam share at 1,084.4 pence in total. This represents a 67% premium over the stock's 650.00p close in London on Tuesday. The offer is supported by Impellam's majority owner Michael Ashcroft, a UK businessman who was formerly deputy chair of the UK Conservative Party.

----------

Allergy Therapeutics PLC, up 9.5% at 2.13p, 12-month range 0.37p-5.64p. The biotechnology firm, focused on allergy vaccines, updates on G306 Phase III trial of Grass MATA MPL, its short-course subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen. It notes "highly significant secondary efficacy endpoints with an acceptable safety and tolerability profile observed for Grass MATA MPL." Chief Executive Manuel Llobet says: "We are very pleased that the primary and secondary endpoints from this trial strongly align, and all data analysed demonstrate the beneficial effect of our Grass MATA MPL product. These data, alongside the results from our earlier G309 field study, provide a strong, significant and consistent data package for our discussions with relevant health authorities."

----------

AIM - LOSERS

----------

Future Metals NL, down 12% at 1.30p, 12-month range 1.13p-6.40p. The West Perth-based exploration company focused on the Panton platinum group metals project in Western Australia says its shares have been suspended on the Australian Securities Exchange in Sydney pending the release of an announcement in relation to a "potential capital raising". The company's shares continue to trade as normal on AIM in London.

----------

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
7 Dec 2015 07:54

Allergy Therapeutics Begins US Phase II Study Of Grass Allergy Vaccine

Read more
30 Nov 2015 09:25

Allergy Therapeutics Completes Patient Enrolment For Birch Study

Read more
17 Nov 2015 14:36

Allergy Therapeutics raises £12m to develop peanut and dust mite treatments

(ShareCast News) - Shares in Allergy Therapeutics fell as, despite a strong trading update, the company launched a £12m discounted fundraising to speed development of treatments for peanut allergy and house dust mites allergies. The AIM-listed company completes the institutional placing by mid-after

Read more
17 Nov 2015 13:03

UPDATE: Allergy Therapeutics Raises GBP11.5 Million To Fund Growth (ALLISS)

Read more
17 Nov 2015 10:14

Allergy Therapeutics To Raise GBP12 Million To Fund Growth (ALLISS)

Read more
16 Nov 2015 16:37

AGM, EGM Calendar - Week Ahead

Read more
4 Nov 2015 10:43

Allergy Therapeutics To Present Adjuvant Data At Spain Conference

Read more
13 Oct 2015 08:43

BROKER RATINGS SUMMARY: Citi Cuts AB Foods As UBS Raises Smiths Group

Read more
21 Sep 2015 08:11

Allergy Therapeutics Says Outlook "Very Positive" As Profit Falls

Read more
14 Sep 2015 14:58

Earnings, Trading Statements Calendar - Week Ahead

Read more
1 Sep 2015 08:35

Allergy Therapeutics Enrols First Patient For Birch Drug Study

Read more
10 Aug 2015 07:23

Allergy Therapeutics Says Paper Published In World Allergy Journal

Read more
27 Jul 2015 16:58

Allergy Technologies' chief executive buys 50,000 shares

(ShareCast News) - The chief executive of Allergy Therapeutics bought new shares in the company few days after releasing a positive trading update. Manuel Llobet purchased 50,000 shares for an individual price of 24.45p, spending a total of £12,225. After the transaction, Llobet holds 3.175m shares

Read more
27 Jul 2015 16:24

DIRECTOR DEALINGS SUMMARY: New MySale Chairman Buys 60,000 Shares

Read more
27 Jul 2015 11:37

DIRECTOR DEALINGS: Allergy Therapeutics CEO Buys 50,000 Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.